Financial Performance - The company's operating revenue for 2022 is expected to be CNY 623,593,117.91, representing a year-on-year increase of 10.66%[6] - The net profit attributable to shareholders is projected to be CNY 160,544,908.20, reflecting a growth of 22.29% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated at CNY 149,943,464.58, which is a 20.32% increase year-on-year[6] - Basic earnings per share are expected to be CNY 0.3761, up 22.29% from the previous year[6] - Total assets at the end of the reporting period are projected to be CNY 1,293,147,896.31, an increase of 7.51% year-on-year[6] - Shareholders' equity attributable to the company is expected to reach CNY 1,086,641,028.20, marking an 8.42% increase compared to the beginning of the year[6] Revenue Growth Drivers - The growth in operating revenue is primarily driven by increased export income from raw material drugs and higher sales of pharmaceutical intermediates[7] - The increase in net profit is attributed to the rise in operating revenue and corresponding gross profit growth[7] Cautionary Notes - The company emphasizes that the financial data presented is preliminary and has not been audited, urging investors to be cautious[8] - The final financial figures will be disclosed in the company's 2022 annual report[8]

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2022-101 江苏森萱医药股份有限公司 关于接待机构投资者调研情况的公告 | --- | |--------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 | | 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 | | 担个别及连带法律责任。 | 江苏森萱医药股份有限公司（以下简称"公司"）于 2022 年 11 月 17 日接 待了 59 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 11 月 17 日 调研形式：网络路演 调研机构：珠海坚果私募基金、中信资产、中信建投基金、中泰证券、中融 基金、中国银河证券、中国国际金融、浙商证券、浙江韶夏投资、长信基金、长 城证券、粤开证券、粤港澳大湾区产融资产、圆信永丰基金、易知（北京）投资、 徐工蓝海（上海）资产、兴业证券、信达澳亚基金、湘财证券、泰信基金、泰康 资产、盛宇投资、深圳 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2022-100 江苏森萱医药股份有限公司 关于接待机构投资者调研情况的公告 | --- | --- | |------------------------------------------------------------------------|-------| | | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | | 带法律责任。 | | 江苏森萱医药股份有限公司（以下简称"公司"）于 2022 年 11 月 8 日接待 了 2 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 11 月 8 日 调研形式：网络调研 调研机构：万家基金、开源证券 上市公司接待人员：财务总监、董事会秘书朱狮章、证券事务代表周剑龙 二、 调研的主要问题及公司回复概要 问题 1：请简单介绍一下公司 2022 年前三季度的经营情况。 回复：2022 年前三季度，公司生产经营稳定，实现收入、利润双增 ...

Financial Performance - The company's operating revenue for the current period reached ¥351,367,667.65, representing a year-on-year increase of 31.61% compared to ¥266,975,261.94 in the previous year [25]. - The net profit attributable to shareholders of the listed company was ¥95,570,133.06, reflecting a growth of 24.98% from ¥76,470,452.18 in the same period last year [25]. - The gross profit margin decreased to 47.02% from 49.95% year-on-year [25]. - The net cash flow from operating activities was ¥79,776,946.84, an increase of 8.19% compared to ¥73,738,385.06 in the previous year [27]. - The company's basic earnings per share rose to ¥0.2239, up 25.01% from ¥0.1791 in the same period last year [25]. - The company reported a net non-recurring profit of ¥7,704,382.07 after tax, with total non-recurring gains amounting to ¥10,564,824.20 [30]. - The company's weighted average return on equity increased to 9.32% from 7.87% year-on-year [25]. - The company achieved operating revenue of 351.37 million yuan, representing a year-on-year growth of 31.61% [35]. - The net profit attributable to shareholders was 95.57 million yuan, reflecting a year-on-year increase of 24.98% [35]. - The net cash flow from operating activities was 79.78 million yuan, up by 8.19% year-on-year [36]. Risks and Challenges - The company faces tax policy risks as some subsidiaries benefit from high-tech enterprise tax incentives, which may be revoked if conditions are not met [13]. - Currency exchange rate fluctuations pose a risk, potentially leading to foreign exchange losses for the company [13]. - The rapid expansion of the company's business has increased accounts receivable, raising the risk of bad debt losses [13]. - Rising raw material prices have been observed, which could negatively impact the company's profitability if the trend continues [13]. - The company operates in a competitive market with numerous domestic and international players, increasing market competition risks [13]. - The ongoing COVID-19 pandemic may adversely affect the company's overseas market activities and cash flow due to restrictions [14]. - International trade tensions, particularly between the US and China, could negatively impact the company's export business and performance [14]. - The company faces risks related to the approval of its raw material drugs and potential market share decline if downstream formulation products do not pass quality evaluations [15]. - The company has a long-term receivable risk related to a land use rights repurchase agreement valued at 52.634 million yuan, with potential bad debt implications [14]. - The company is at risk of significant bad debt losses if the loan from Tai Xing Hong Qiao Industrial Development Co., Ltd. is not recovered in a timely manner [90]. Environmental and Safety Management - The company has strengthened safety and environmental management, with no major accidents reported during the period [36]. - The company has implemented pollution prevention facilities, including two sets of waste gas incinerators with capacities of 30,000 m³/h and 50,000 m³/h, ensuring compliance with environmental standards [63]. - The wastewater treatment facility has a daily processing capacity of 1,000 tons, with ongoing construction of additional treatment systems [64]. - The company has established three standardized solid waste storage facilities to manage solid waste effectively, ensuring compliance with disposal regulations [64]. - The company has installed online monitoring devices at all emission outlets, with data connected to provincial and municipal platforms for real-time tracking [65]. - The company’s waste gas treatment includes a two-stage activated carbon adsorption process, ensuring that emissions meet regulatory standards [65]. - The company has a comprehensive environmental protection strategy, including the management of hazardous waste through qualified disposal units [65]. - The company has not experienced any environmental pollution incidents to date, indicating effective operational management [67]. - The company has conducted regular training and drills to improve emergency response capabilities for environmental incidents [72]. Research and Development - Research and development expenses rose to CNY 17.77 million, maintaining a steady 5.06% of operating revenue, with a year-over-year increase of 31.47% [44]. - The company is actively increasing R&D investment to ensure compliance with high-tech enterprise qualifications and tax incentives [79]. - The company is enhancing R&D efforts and optimizing product processes to address market competition risks from both domestic and international players [83]. - The company is accelerating the R&D and production of its raw materials to mitigate the risk of not passing the associated review [92]. Commitments and Governance - The company is currently fulfilling commitments related to stabilizing stock prices made during the public issuance of shares on May 19, 2020 [102]. - The company has ongoing commitments to compensate for the dilution of immediate returns as per the public issuance of shares on May 19, 2020 [102]. - The company is actively fulfilling commitments regarding profit distribution policies made during the public issuance of shares on May 19, 2020 [102]. - The company has committed to enhancing management efficiency and controlling expenses to improve operational efficiency and profitability [118]. - The company will implement measures to ensure that the commitments regarding the replenishment of diluted immediate returns are fulfilled [120]. - The company has pledged to compensate investors for losses incurred due to misleading statements in the public offering documents [132]. - The company will publicly disclose reasons for any failure to fulfill commitments and will apologize to shareholders and investors [136]. Market and Operational Strategy - The company is focusing on expanding its market presence and developing new technologies to enhance its competitive edge [176]. - Future guidance indicates a continued emphasis on improving operational efficiency and exploring potential mergers and acquisitions to drive growth [176]. - The company is exploring markets in regions less affected by the COVID-19 pandemic to mitigate risks associated with the ongoing health crisis [87]. - The company is adjusting its market strategy to reduce exposure to international trade tensions and protect its export business [88].

Financial Performance - Total revenue for Q1 2022 reached ¥182,603,038.82, representing a year-on-year increase of 30.63% compared to ¥139,788,669.27 in Q1 2021[14] - Net profit attributable to shareholders for Q1 2022 was ¥49,972,953.24, up 23.47% from ¥40,474,012.63 in the same period last year[14] - The net cash flow from operating activities increased by 57.04% to ¥41,670,594.01, compared to ¥26,534,388.23 in Q1 2021[14] - Basic earnings per share for Q1 2022 were ¥0.1171, reflecting a 23.52% increase from ¥0.0948 in Q1 2021[14] - The total sales revenue for the period was ¥114,578,823.47, compared to ¥114,860,708.39 in the previous period, indicating a slight decrease[20] - The company reported a net increase in cash and cash equivalents of ¥53,571,634.59, up from ¥52,076,721.26 in the previous period[20] - Total operating revenue for the period was 120,725,024.05, an increase from 89,254,377.61 in the previous period, reflecting a growth of approximately 35.3%[80] - Net profit for the period reached 53,340,658.13, compared to 43,454,614.55 in the same period last year, representing an increase of about 22.5%[81] Assets and Liabilities - Total assets as of March 31, 2022, were ¥1,239,285,533.57, a 3.03% increase from ¥1,202,864,513.38 at the end of 2021[14] - The net assets attributable to shareholders increased by 5.06% to ¥1,052,935,234.63 from ¥1,002,268,468.65 at the end of the previous year[14] - The company's debt-to-asset ratio decreased to 9.55% from 11.33% year-on-year, indicating improved financial stability[14] - Total liabilities decreased to ¥118,355,182.45 from ¥136,233,225.53, indicating a reduction of approximately 13.1%[73] - Current liabilities totaled ¥112,854,794.80, down from ¥130,248,976.17, showing a decline of around 13.3%[72] - Non-current liabilities were reported at ¥5,500,387.65, a slight decrease from ¥5,984,249.36, representing a reduction of about 8.0%[73] - Shareholders' equity increased to ¥1,120,930,351.12 from ¥1,066,631,287.85, marking a growth of approximately 5.1%[73] Cash Flow - The company's cash and cash equivalents at the end of the period amounted to ¥358,923,697.42, an increase from ¥359,406,262.86 at the beginning of the period[20] - The total cash paid for taxes during the period was ¥12,418,704.66, slightly down from ¥12,483,047.84 in the previous period[20] - Operating cash flow for Q1 2022 was CNY 41,670,594.01, a 57% increase from CNY 26,534,388.23 in Q1 2021[85] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 313,683,749.03, down from CNY 359,406,262.86 at the end of Q1 2021[86] - The company experienced a net decrease in cash and cash equivalents of CNY 15,624,365.24 in Q1 2022, compared to an increase of CNY 8,656,465.11 in Q1 2021[88] Shareholder Commitments and Governance - The commitments made during the company's listing are currently being fulfilled by the board members and major shareholders[31] - The commitments related to major asset restructuring have been completed, while some are still in progress, including those concerning independence and liability for losses[32] - The company has a plan to stabilize its stock price for three years post-listing, which includes specific measures to be taken if the stock price falls below the audited net asset value per share[34] - The company can repurchase shares if the stock price remains below the audited net asset value for ten consecutive trading days after implementing profit distribution or capital reserve conversion[37] - The controlling shareholder is required to propose a plan to increase their shareholding if the stock price remains low after the repurchase[38] - The company will require new directors and senior management to sign commitments to uphold stock price stabilization measures[41] - The company’s controlling shareholder has committed not to interfere with the company's management or harm its interests[43] Profit Distribution Policy - The company has developed a profit distribution policy to ensure stable and reasonable returns for investors, considering factors like profitability and cash flow[45] - The company will implement a continuous and stable profit distribution policy, with annual profit distribution plans proposed by the board of directors[46] - The company adopts a cash, stock, or a combination of both methods for profit distribution, prioritizing cash distribution[48] - The company plans to distribute at least 10% of the annual distributable profit in cash when conditions are met, and at least 30% of the average annual distributable profit over any three consecutive years[49] - The company aims to maintain a cash dividend ratio of at least 80% for mature stages without significant capital expenditure, and at least 40% with significant capital expenditure[49] Compliance and Legal Responsibilities - The controlling shareholder guarantees the authenticity and completeness of the public offering application documents, accepting legal responsibility for any inaccuracies[56] - All directors, supervisors, and senior management confirm the accuracy of the public offering application documents and accept legal responsibility[57] - The underwriter and auditing firm have committed to the accuracy of the public offering documents, agreeing to compensate investors for any losses caused by inaccuracies[57] - The company will publicly explain any failure to fulfill commitments and apologize to shareholders if such failures occur[60] - The company will ensure compliance with legal regulations regarding shareholding and will bear responsibility for any violations[56]

Company Overview - Jiangsu Senxuan Pharmaceutical successfully transitioned to the Beijing Stock Exchange, becoming one of the first companies listed there[3]. - The company was listed on the Beijing Stock Exchange on November 15, 2021, marking a significant milestone in its growth strategy[22]. - The company’s total share capital is 426,918,340 shares, reflecting its scale in the pharmaceutical manufacturing sector[22]. - The company’s actual controller is the State-owned Assets Supervision and Administration Commission of Nantong City, ensuring government oversight[23]. Financial Performance - The company's total revenue for 2021 was $563.54 million, representing a year-over-year increase of 2.78% compared to $548.28 million in 2020[28]. - The net profit attributable to shareholders decreased by 9.38% to $131.28 million in 2021 from $144.87 million in 2020[28]. - The gross profit margin for 2021 was 44.87%, down from 48.36% in 2020[28]. - Total assets increased by 7.42% to $1.20 billion at the end of 2021, compared to $1.12 billion at the beginning of the year[30]. - The total liabilities rose by 26.45% to $136.23 million at the end of 2021, up from $107.74 million at the beginning of the year[30]. - The company's interest coverage ratio was 538.37 in 2021, significantly higher than 43.70 in 2020[30]. - The net cash flow from operating activities was $174.42 million, a decrease of 3.19% from $180.17 million in 2020[32]. - The company's basic earnings per share decreased by 16.80% to $0.3075 in 2021 from $0.3696 in 2020[28]. - The net profit growth rate for 2021 was -9.73%, contrasting with a growth rate of 34.00% in 2020[33]. - Non-recurring gains and losses totaled $8.34 million in 2021, down from $15.85 million in 2020[39]. Production and Capacity - The subsidiary Luhua Senxuan completed the trial production of a 6,000-ton expansion project for Dioxane, indicating growth in production capacity[3]. - The company has established a stable raw material supply system to mitigate risks associated with supply chain disruptions[14]. - The company has completed the trial production of its subsidiary's expansion project[47]. - The company has implemented a project to improve the production of 6,000 tons/year of 1,4-Dioxane, which has led to a reduction in organic waste from 21.87 Kg/ton to 15.99 Kg/ton after the upgrade[109]. Research and Development - The company is currently assessing the commercialization of 12 raw material drug technologies, with uncertain cash flow predictions[10]. - Research and development expenses increased by 11.31% to CNY 28,102,839.63, reflecting the company's commitment to innovation[57]. - The total number of R&D personnel increased from 82 to 100, with the proportion of R&D staff to total employees rising from 13.10% to 15.77%[82]. - The company holds 100 patents, up from 77, including 14 invention patents, an increase from 11[84]. - The company is actively engaged in collaborative R&D projects with universities, focusing on the development of new synthesis routes and processes for various chemical products[86]. Market Position and Strategy - The company was selected for the Jiangsu Province "Specialized, Refined, and New" small giant enterprise cultivation project, reflecting its innovation and market position[3]. - The company aims to enhance its market share in oxygen-containing heterocyclic intermediates, being one of the largest suppliers of Dioxane products in China[113]. - The company has established a strategy to refine its raw material drug product structure and strengthen its position in the high-end market while maintaining cost competitiveness in the low-end market[112]. - The raw material drug market in China is experiencing a shift towards specialty raw materials, with increasing competition expected as companies transition from bulk to specialty products[110]. Risks and Challenges - The company faces risks related to raw material price fluctuations, which could adversely affect profitability if prices continue to rise[10]. - The company has a significant reliance on tax incentives for high-tech enterprises, which poses a risk if it no longer qualifies for these benefits[10]. - The company’s accounts receivable may increase due to rapid business expansion, raising the risk of bad debt losses[10]. - The ongoing COVID-19 pandemic has the potential to negatively impact overseas market activities and customer payment collections[10]. - The company faces significant competition from raw material manufacturers in developing countries, particularly India, which has increased pressure on production costs and product pricing[14]. - Regulatory changes in the pharmaceutical industry may pose risks, as the company must adapt to evolving market rules and compliance requirements[13]. - The company is exposed to tax policy risks, particularly regarding high-tech enterprise tax incentives, which could impact operations if conditions change[118]. - The company faces risks from stricter environmental regulations that may increase production costs and eliminate non-compliant enterprises[117]. Environmental Compliance - The company emphasizes environmental protection and compliance with local regulations, ensuring a positive impact on the community[91]. - The company has a wastewater treatment station with a daily processing capacity of 1,000 tons and is constructing a biochemical facility to enhance wastewater treatment capacity[95]. - The company has completed environmental impact assessments for its projects, with approvals from local environmental protection bureaus[99]. - The company has established a monitoring system for environmental compliance, including real-time data transmission to local environmental authorities[106]. Shareholder Commitments and Governance - The company commits to publicly explaining any failure to implement stock price stabilization measures and apologizing to shareholders[154]. - The controlling shareholder has committed not to interfere with the company's management or harm its interests[159]. - All directors and senior management have pledged to ensure the fulfillment of the company's return measures and not to misuse company assets[160]. - The company will actively promote profit distribution to shareholders in accordance with legal regulations and internal policies[158]. - The company has ongoing commitments regarding the handling of asset restructuring and ensuring independence in operations, assets, and finances as of July 19, 2018[145].

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2021-059 江苏森萱医药股份有限公司 关于接待机构投资者调研情况的公告 | --- | |--------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 | | 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 | | 担个别及连带法律责任。 | 江苏森萱医药股份有限公司（以下简称"公司"）于 2021 年 11 月 19 日接 待了 4 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2021 年 11 月 19 日 调研形式：腾讯会议） 调研机构：易方达基金、安信证券、东北证券、粤开证券 上市公司接待人员：董事长吴玉祥、董事会秘书兼财务负责人朱狮章 二、 调研的主要问题及公司回复概要 问题 1：请问公司原料药产品销量、成本端的变化情况如何、成本端的变 化如何化解？ 回复：公司原料药产品的销量基本平稳；在成本端受双控政策原料药涨价 的影响， ...